BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37996430)

  • 1. Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML.
    Negri A; Ward C; Bucci A; D'Angelo G; Cauchy P; Radesco A; Ventura AB; Walton DS; Clarke M; Mandriani B; Pappagallo SA; Mondelli P; Liao K; Gargano G; Zaccaria GM; Viggiano L; Lasorsa FM; Ahmed A; Di Molfetta D; Fiermonte G; Cives M; Guarini A; Vegliante MC; Ciavarella S; Frampton J; Volpe G
    Cell Death Dis; 2023 Nov; 14(11):763. PubMed ID: 37996430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent
    Matsuo H; Yoshida K; Fukumura K; Nakatani K; Noguchi Y; Takasaki S; Noura M; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Shiba N; Yamato G; Handa H; Ono Y; Hiramoto N; Ishikawa T; Usuki K; Ishiyama K; Miyawaki S; Itonaga H; Miyazaki Y; Kawamura M; Yamaguchi H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Hayashi Y; Mano H; Miyano S; Kamikubo Y; Ogawa S; Adachi S
    Blood Adv; 2018 Nov; 2(21):2879-2889. PubMed ID: 30381403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanism of MYB transcriptional regulation by MLL-AF9 oncoprotein.
    Cao L; Mitra P; Gonda TJ
    Sci Rep; 2019 Dec; 9(1):20084. PubMed ID: 31882723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HOXA9 is required for survival in human MLL-rearranged acute leukemias.
    Faber J; Krivtsov AV; Stubbs MC; Wright R; Davis TN; van den Heuvel-Eibrink M; Zwaan CM; Kung AL; Armstrong SA
    Blood; 2009 Mar; 113(11):2375-85. PubMed ID: 19056693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Dysregulated DNA Methylation Landscape Linked to Gene Expression in MLL-Rearranged AML.
    Koldobskiy MA; Abante J; Jenkinson G; Pujadas E; Tetens A; Zhao F; Tryggvadottir R; Idrizi A; Reinisch A; Majeti R; Goutsias J; Feinberg AP
    Epigenetics; 2020 Aug; 15(8):841-858. PubMed ID: 32114880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
    Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
    Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
    Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
    Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
    Jiang X; Huang H; Li Z; He C; Li Y; Chen P; Gurbuxani S; Arnovitz S; Hong GM; Price C; Ren H; Kunjamma RB; Neilly MB; Salat J; Wunderlich M; Slany RK; Zhang Y; Larson RA; Le Beau MM; Mulloy JC; Rowley JD; Chen J
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19397-402. PubMed ID: 23132946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.
    Placke T; Faber K; Nonami A; Putwain SL; Salih HR; Heidel FH; Krämer A; Root DE; Barbie DA; Krivtsov AV; Armstrong SA; Hahn WC; Huntly BJ; Sykes SM; Milsom MD; Scholl C; Fröhling S
    Blood; 2014 Jul; 124(1):13-23. PubMed ID: 24764564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant TRPM4 expression in MLL-rearranged acute myeloid leukemia and its blockade induces cell cycle arrest via AKT/GLI1/Cyclin D1 pathway.
    Wang F; Wu P; Gong S; Chen Y; Gao J; Wang S; Shen Q; Tao H; Hua F; Zhou Z; Zou Z; Ma T; Jia Y
    Cell Signal; 2020 Aug; 72():109643. PubMed ID: 32320859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting acute myeloid leukemia by drug-induced c-MYB degradation.
    Walf-Vorderwülbecke V; Pearce K; Brooks T; Hubank M; van den Heuvel-Eibrink MM; Zwaan CM; Adams S; Edwards D; Bartram J; Samarasinghe S; Ancliff P; Khwaja A; Goulden N; Williams G; de Boer J; Williams O
    Leukemia; 2018 Apr; 32(4):882-889. PubMed ID: 29089643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.
    Willer A; Jakobsen JS; Ohlsson E; Rapin N; Waage J; Billing M; Bullinger L; Karlsson S; Porse BT
    Leukemia; 2015 May; 29(5):1018-31. PubMed ID: 25349154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
    Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
    J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
    Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
    Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SUMO modification regulates MafB-driven macrophage differentiation by enabling Myb-dependent transcriptional repression.
    Tillmanns S; Otto C; Jaffray E; Du Roure C; Bakri Y; Vanhille L; Sarrazin S; Hay RT; Sieweke MH
    Mol Cell Biol; 2007 Aug; 27(15):5554-64. PubMed ID: 17548468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the undruggable: menin inhibitors ante portas.
    Dempke WCM; Desole M; Chiusolo P; Sica S; Schmidt-Hieber M
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9451-9459. PubMed ID: 37103568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fetal tumor suppressor axis abrogates MLL-fusion-driven acute myeloid leukemia.
    Eldeeb M; Yuan O; Guzzi N; Thi Ngoc PC; Konturek-Ciesla A; Kristiansen TA; Muthukumar S; Magee J; Bellodi C; Yuan J; Bryder D
    Cell Rep; 2023 Feb; 42(2):112099. PubMed ID: 36763502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.
    Wang Y; Skibbe JR; Hu C; Dong L; Ferchen K; Su R; Li C; Huang H; Weng H; Huang H; Qin X; Jin J; Chen J; Jiang X
    Sci Rep; 2017 May; 7(1):1853. PubMed ID: 28500307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia.
    Chen P; Price C; Li Z; Li Y; Cao D; Wiley A; He C; Gurbuxani S; Kunjamma RB; Huang H; Jiang X; Arnovitz S; Xu M; Hong GM; Elkahloun AG; Neilly MB; Wunderlich M; Larson RA; Le Beau MM; Mulloy JC; Liu PP; Rowley JD; Chen J
    Proc Natl Acad Sci U S A; 2013 Jul; 110(28):11511-6. PubMed ID: 23798388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.